Axial Spondyloarthritis | Unmet Need | Nonradiographic Axial Spondyloarthritis | US/EU | 2023
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Simponi, and UCB’s Cimzia) are approved to treat nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe and are increasingly used off-label in the United States, where Cimzia is the only FDA-approved TNF-α inhibitor for nr-AxSpA. Additionally, two IL-17 inhibitors—Novartis’s Cosentyx and Eli Lilly’s Taltz—and a JAK inhibitor—AbbVie’s Rinvoq—were recently approved for this subpopulation in both regions. In this report, we examine areas of unmet need in the treatment of nr-AxSpA, including short-term efficacy, improvement in patient-reported quality of life, mechanism of action, safety and tolerability, delivery, and price. With quantitative insight into U.S. and European rheumatologists’ assessment of the unmet need in the treatment of nr-AxSpA, we discuss the commercial opportunities for this difficult-to-diagnose indication and how emerging therapies may capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for nr-AxSpA?
- Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for nr-AxSpA?
- What are the prevailing areas of unmet need and opportunity in nr-AxSpA?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new nr-AxSpA drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 31 European rheumatologists fielded in April 2023
Key companies: AbbVie, Amgen, UCB, Novartis, Eli Lilly
Key drugs: Humira, Enbrel, Cimzia, Cosentyx, Taltz, Rinvoq, NSAIDs
